

CHRYSOS CORPORATION
Assays at the speed of light

Faster, more accurate **gold** analysis

Annual General Meeting

25 November 2026

Rob Adamson, Chair

Important notice

The material in this presentation has been prepared by Chrysos Corporation Limited (ASX: C79) (“Chrysos” or the “Group") and is general background information about Chrysos’ current activities as at the date of this presentation. The information is given in summary form and does not purport to be complete. It is intended to be read by a professional analyst audience in conjunction with the Company’s other announcements to ASX. Information in this presentation, including forecast financial information, should not be considered advice or a recommendation to current shareholders, investors or potential investors, in relation to holding, purchasing or selling securities in the Company, and does not take into account the investment objectives, financial situation or needs of any particular shareholder or investor. No representation or warranty, express or implied, is made as to the accuracy, reliability, adequacy or completeness of the information contained in this presentation.

Forward-looking statements

This presentation may contain statements that are, or may be deemed to be, forward-looking statements, for example statements that use words such as “may”, “will”, “would”, “could”, “expects”, “intends”, “anticipates”, and other similar words that involve risks and uncertainties. You should not place undue reliance on such forward-looking statements. These statements are based on an assessment of present economic and operating conditions and on a number of best estimate assumptions regarding future events and actions that, at the date of this document, are expected to take place. No person who has made any forward-looking statements in this document has any intention to update or revise forward-looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this document, other than to the extent required by law. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company.

This presentation also contains references to certain intentions, expectations and plans of the Company. These intentions, expectations and plans may or may not be achieved. They are based on certain assumptions which may not be met or on which views may differ.

This presentation may contain information that has been derived from publicly available sources that have not been independently verified. No representation or warranty, express or implied, is made as to the accuracy, reliability, adequacy or completeness of this information.

Past performance information in this presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of future performance

To the maximum extent permitted by law, Chrysos, its subsidiaries and their respective officers, employees, agents and consultants, and any other person involved in the preparation of this presentation, disclaim all liability and responsibility, including, without limitation, any liability arising out of fault or negligence, for any direct or indirect loss which may arise from or be suffered through use or reliance on anything contained in, or omitted from, this presentation.

Agenda

01 Chair Address

02 CEO Address

03 Questions & Answers

04 Items of Business





CHRYSOS CORPORATION
Assays at the speed of light

Chair Address

Rob Adamson

CHRYSOS CORPORATION
Assays at the speed of light



Managing Director & CEO Address

Financial and operating highlights

Strong start to FY27 supported by industry activity

$36.7m

Total Revenue (July to October 2026)[1]

- +27% growth versus PCP
- MMAP Revenue of $22.6m (+7% PCP), AAC Revenue of $13.7m (+79% PCP)
- **Reflects ongoing global adoption of PhotonAssay™ and strong utilisation**

4.91m

PhotonAssay™ Samples (July to October 2026)

- +43% growth versus PCP
- PhotonAssay™ fleet sustaining above 90% availability at high utilisation
- **Record sample volumes drive AAC Revenue to 38%**

$139.5m

Funding position[1]

- Operating cash-flow positive
- Funding position includes $19.5m cash and $120m in undrawn debt
- **Well-funded to support increased manufacturing cadence of PhotonAssay™ units**

51

Deployed units[2]

- Six units deployed YTD in FY27 and six units currently deploying
- 15 lease agreements signed during FY27, bringing total contracted units to 97[3]
- **Increasing strength and quality of leased pipeline supports deployments**

1. Unaudited as at 31 October 2026
2. As at 19 November 2026 and includes the decommissioning of MSA's Bamako unit, preannounced in the May 2026 release
3. Net of an MSA unit cancelled since the 30 June 2026 and replaced with the Paramaribo unit (previously announced)

PhotonAssay™ Sample Volumes

CHRYSOS CORPORATION

Continued conversion to PhotonAssay™ and strong utilisation of our deployed fleet

YTD PhotonAssay™ Samples Analysed



Activity Commentary

- Sustained PhotonAssay™ demand, with volumes exceeding 1m samples every month since March 2026
- October samples processed of 1.36m, up 48% PCP demonstrating consistent, strong usage across our growing deployed fleet
- Monthly throughput growing consistently between 36–48% in FY27 YTD
- Industry outlook remains positive, supported by an elevated gold price, continued exploration activity and production outlook

Unaudited Revenue

- YTD revenue of $36.7m[1], comprising $22.6m MMAP and $13.7m AAC
- Additional assay charges (AAC) now represent 38% of PhotonAssay™ revenue, up from 26% for the four months to 31 October 2025
- Six new PhotonAssay™ units deployed since 30 June 2026, taking the global fleet to 51 units[2]

1. Revenue is unaudited as at 31 October 2026
2. One unit in Mali decommissioned for redeployment in the region in FY27

Executing on our global PhotonAssay™ roll-out

Strengthening relationships with key miners and laboratories

51 Units Deployed[1]



YTD Activity (as at 19 November 2026)

- **Six units deployed in FY27**
  - BV – Kalgoorlie, Australia
  - ALS – Rouyn Noranda, Canada
  - ALS – Surrey, Canada
  - Aurenne – Mt Ida Gold Mine, Australia
  - MSA – Paramaribo, Suriname
  - MSA – Korhogo, Ivory Coast
- **Six units currently being deployed**
  - Newmont – Ahafo, Ghana
  - Newmont – Merian, Suriname
  - Acrux – Cononish Gold Mine, Scotland
  - Afrilabs – Addi Baba, Morocco
  - ALS – Sodankyla, Finland
  - SGS – West Red Lake, Canada
- **15 new lease agreements signed in FY27**
  - Four direct to mine lease agreements
  - Four units with SGS (including one mine-site unit)
  - Two units with BV
  - Four units with ALS
  - One unit with Alfred H Knight

PhotonAssay™ units on five continents in key mining hubs

1. Includes six new units deployed net of one unit decommissioned with MSA in Mali (pre-announced)

PhotonAssay™ deployments

Global fleet supporting future growth

Total PhotonAssay™ Units

59 → 66 **+ 7**

Units manufactured since Aug 2026 Results

Deployed PhotonAssay™ Units

46 → 51 **+ 5**

Net of the Mali unit which has been demobilised

Contracted PhotonAssay™ Units

87 → 97 **+ 10**

From Aug 2026 Results to Nov 2026

PhotonAssay™ deployment pipeline

Pre-ship or stored
4
Nov 2026
August: 3 | Δ +1

Shipping to site
0
Nov 2026
August: 1 | Δ −1

Awaiting installation
4
Nov 2026
August: 5 | Δ -1

Deploying
6
Nov 2026
August: 6 | Δ +0

Deployed
51
Nov 2026
August: 46 | Δ +5

Redeployments
1
Nov 2026
August: 1 | Δ +0

◂ *Furthest from operational*

Operational

- Six units deployed YTD in FY27
- Seven newly manufactured units supporting customer demand
- Four units pre-installation and a further four waiting installation, both support further FY27 deployments
- One redeployment currently underway of the MSA Bamako unit, which has now been decommissioned (as previously announced)
- Decommissioned MSA Obuasi unit currently being redeployed in Morocco (included in Deploying units)

Doubling our deployed fleet by FY29

CHRYSOS CORPORATION

Contracted pipeline underpins our target of 90 deployed PhotonAssay™ units by the end of FY29

PhotonAssay™ Units Deployed (end of financial year)



Pathway to 90 Units

- Manufacturing cadence increased to 18 units per year, supporting the pathway to 90 deployed units
- Growing share of contracts signed directly with Tier 1 miners and with major global laboratory groups, derisking deployment timing
- 97 total contracted units, already exceeding our FY29 target of 90 deployed units
- Well-funded, with a $139.5m funding position and operating cash-flow positive

51	97	90
Units deployed	Total contracted units	FY29 deployed target

1. FY24 to FY26 shown as units deployed at 30 June. FY27 as at 19 November 2026; FY27 opening fleet excludes one Mali unit decommissioned for redeployment in the region.

Financial Highlights

CHRYSOS CORPORATION

Record sample volumes continue to underpin revenue



FY27 Guidance

- Reiterated FY27 guidance[1] of:
  - FY27 Revenue range of $108m to $118m
  - FY27 EBITDA range of $35m to $42m

Cash & Debt Position

- Cash on hand $19.5m
- $200m debt facility in place, of which $80m has been drawn
- Well-funded to support PhotonAssay™ unit growth

1. Constant currency assumptions (AUD:USD 0.6934, AUD:CAD 0.9627, AUD:GBP 0.522, AUD:EUR 0.6018, AUD:NZD 1.1923, AUD:GHS 8.541)



CHRYSOS CORPORATION
Assays at the speed of light

Questions & Answers



CHRYSOS CORPORATION
Assays at the speed of light

Items of Business

Item 1: Consideration of Reports

CHRYSOS CORPORATION

Financial Report, Directors' Report and Auditor's Report

To receive and consider the Financial Report, the Directors' Report, and the Independent Auditor's Report of the Company for the Financial Year ended 30 June 2026.

All shareholders can view the Annual Report, which contains the Financial Report, the Directors' Report, and the Independent Auditor's Report of the Company for the year ended 30 June 2026, on the Company's website at www.chrysoscorp.com/investor-centre

Item 2

Adoption of Remuneration Report

To consider and, if thought fit, to pass the following resolution as an ordinary resolution:

"That, for the purposes of section 250R(2) of the Corporations Act, the Company's Remuneration Report for the year ended 30 June 2026 be adopted."

For	Open	Against	Abstain
71,536,828	35,006	38,501	2,630

Note: the vote on this resolution is advisory only and does not bind the Directors or the Company. A voting exclusion applies to this resolution

Item 3(a)

Re-election of Directors retiring by rotation – Robert Adamson

To consider and, if thought fit, to pass, the following resolution as an ordinary resolution:

"*That Robert Adamson, a director who retires by rotation in accordance with Rule 38.1(c) of the Company's constitution and, being eligible, offers himself for re-election, be re-elected as a director of the Company.*"

For	Open	Against	Abstain
74,121,320	27,106	585	3,000

Item 3(b)

CHRYSOS CORPORATION

Re-election of Directors retiring by rotation – Eric Ford

To consider and, if thought fit, to pass the following resolution as an ordinary resolution:

"That Eric Ford, a director who retires by rotation in accordance with Rule 38.1(c) of the Company's constitution and, being eligible, offers himself for re-election, be re-elected as a director of the Company."

For	Open	Against	Abstain
73,810,820	27,106	585	313,500

Item 4

Approval of Rights Plan

To consider and, if thought fit to pass the following resolution as an ordinary resolution:

"That, for the purposes of ASX Listing Rule 7.2 (Exception 13) and for all other purposes, shareholders approve the employee incentive scheme known as the Chrysos Corporation Limited Rights Plan (the "Rights Plan"), and the issue of equity securities under it, on the terms summarised in the explanatory notes."

For	Open	Against	Abstain
72,960,830	25,056	1,164,405	1,720

Note: A voting exclusion applies to this resolution

Item 5

Approval of FY27 MD & CEO LTI Award

To consider and, if thought fit, to pass the following resolution as an ordinary resolution:

"That, subject to the passing of Item 4, for the purposes of ASX Listing Rule 10.14, and for all other purposes, approval is given for the Company to grant 237,209 Performance Rights to Mr Treasure to satisfy the FY27 MD & CEO LTI Award under the Rights Plan, on the terms summarised in the explanatory notes."

For	Open	Against	Abstain
72,928,430	25,056	1,192,185	6,340

Note: A voting exclusion applies to this resolution

Item 6(a)

CHRYSOS CORPORATION

Approval of potential LTI termination benefits for Dirk Treasure

To consider and, if thought fit, to pass the following resolution as an ordinary resolution:

"That, for the purposes of satisfying the procedural requirements in sections 200B and 200E of the Corporations Act, and for all other purposes, approval is given for the Company to provide potential termination benefits to Dirk Treasure related to the 237,209 Performance Rights to be granted to Mr Treasure under the Rights Plan (subject to shareholder approval under Item 5) in FY27 and in connection with Mr Treasure's loss of position from a managerial or executive office with the Company or a related body corporate, on the terms described in the explanatory notes."

For	Open	Against	Abstain
72,910,006	24,556	1,210,089	7,360

Note: A voting exclusion applies to this resolution

Item 6(b)

CHRYSOS CORPORATION

Approval of potential LTI termination benefits for Brett Coventry

To consider and, if thought fit, to pass the following resolution as an ordinary resolution:

"That, for the purposes of satisfying the procedural requirements in sections 200B and 200E of the Corporations Act, and for all other purposes, approval is given for the Company to provide potential termination benefits to Brett Coventry related to the 96,968 Performance Rights to be granted to Mr Coventry under the Rights Plan in FY27 and in connection with Mr Coventry's loss of position from a managerial or executive office with the Company or a related body corporate, on the terms described in the explanatory notes."

For	Open	Against	Abstain
72,910,006	24,556	1,210,089	7,360

Note: A voting exclusion applies to this resolution



CHRYSOS CORPORATION
Assays at the speed of light

Voting & Poll

Official Meeting Close

For more information, please visit **chrysoscorp.com**
or contact us at **investors@chrysoscorp.com**

CHRYSOS CORPORATION
Assays at the speed of light

Thank you

For more information, please visit **chrysoscorp.com**
or contact us at **investors@chrysoscorp.com**

CHRYSOS
CORPORATION
Assays at the speed of light